# United Therapeutics (UTHR) — Overview

UTHR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/uthr

## Price

Last close $541.51 on Oct 15, 2026. 52-week range $415.34 – $596.76.

## Company profile

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $3.2B |
| Revenue (quarter) | $783.3M |
| Revenue growth (year over year) | -1.92% |
| Gross profit (trailing twelve months) | $2.7B |
| Gross margin | 86.14% |
| Net income (trailing twelve months) | $1.3B |
| Net income (quarter) | $333.0M |
| Net income growth (year over year) | 7.59% |
| Net margin | 41.56% |
| Return on equity | 19.32% |
| EPS (trailing twelve months) | $30.23 |
| Book value per share | $149.97 |
| P/E (trailing twelve months) | 17.7 |
| Price to book | 3.6 |
| Debt to assets | 11.35% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is United Therapeutics (UTHR) profitable?

Yes. United Therapeutics earned $1.3B in net income over the trailing twelve months, a net margin of 41.56%.

### How much revenue does United Therapeutics (UTHR) make?

United Therapeutics generated $3.2B in revenue over the trailing twelve months, down 1.92% year over year.

### What is UTHR's P/E ratio?

United Therapeutics trades at 17.7 times trailing twelve-month earnings, on an EPS of $30.23.

### How do I buy stock in United Therapeutics (UTHR)?

UTHR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).